North East and North Cumbria
ICS Formulary
10 Musculoskeletal and joint diseases
10-02 Drugs used in neuromuscular disorders
Mexiletine
Namuscla
®
Formulary
Approved for the treatment of myotonia in patients with non-dystrophic myotonic disorders
in line with NICE and NHSE commissioning policy (SSC2001).
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
Nusinersen
Spinraza
®
Formulary
12mg solution for injection
Approved as an option for treating 5q spinal muscular atrophy (SMA) types 1, 2 or 3 in line with NICE.
NHS England Urgent Clinical Commissioning Policy Statement (170018/P)
NICE TA588: Nusinersen for treating spinal muscular atrophy
Risdiplam
Evrysdi
®
Formulary
0.75mg/1ml oral solution
Approved for treating spinal muscular atrophy in line with NICE
To be provided by Newcastle Hospitals homecare service
only
NICE TA755: Risdiplam for treating spinal muscular atrophy
Links
Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
NHS England Urgent Clinical Commissioning Policy Statement (170018/P)
NICE TA588: Nusinersen for treating spinal muscular atrophy
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
NICE TA755: Risdiplam for treating spinal muscular atrophy
NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence
Key
Full Site